Rathbones Group PLC Has $14.20 Million Position in Pfizer Inc. (NYSE:PFE)

Key Points

• Rathbones Group PLC reduced its stake in Pfizer Inc. by 4.2% during the first quarter, selling 24,542 shares and now holding 560,515 shares valued at $14.2 million.
• Multiple institutional investors, including Bessemer Group Inc. and Alta Advisers Ltd., increased their positions in Pfizer during the same period, highlighting ongoing interest in the company.
• Current analyst ratings suggest a consensus of "Hold" for Pfizer's stock, with a consensus price target of $28.12, despite fluctuations in price targets from various analysts.

Rathbones Group PLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 560,515 shares of the biopharmaceutical company's stock after selling 24,542 shares during the period. Rathbones Group PLC's holdings in Pfizer were worth $14,203,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock valued at $1,548,889,000 after buying an additional 4,167,222 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Pfizer by 3.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after buying an additional 1,333,740 shares during the period. Invesco Ltd. raised its holdings in shares of Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Finally, TD Cowen dropped their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.05 during trading on Friday, reaching $25.16. The company had a trading volume of 31,506,212 shares, compared to its average volume of 45,618,887. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The stock has a market cap of $143.05 billion, a PE ratio of 13.38, a PEG ratio of 0.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business's 50 day moving average price is $24.56 and its 200-day moving average price is $24.46.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.60 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.